MAP2K1 and colorectal carcinoma: Additionally, pharmacological blockade of this resistance pathway using the cMET inhibitor crizotinib (formerly PF-02341066) increased MEK1/2-inhibitor-induced apoptosis and growth inhibition in vitro and in vivo in KRASMT CRC models [18].